Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04735978 · ClinicalTrials.gov registry record · Phase 1

Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours

A Phase 1 study of Advanced Solid Tumor, sponsored by Replimune.

Active
Registry status
Phase 1
Development phase
123
Enrollment target
13
Study locations

NCT04735978 is a Phase 1 study of Advanced Solid Tumor that is active but no longer recruiting, run by Replimune. The registered enrollment target is 123 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (36% lower). The trial reports 13 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04735978, a Phase 1 study of Advanced Solid Tumor, is active but no longer recruiting, sponsored by Replimune.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
123 participants
Enrollment target
13
Study locations

Study Summary

This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recommended Phase 2 dose (RP2D) of RP3.

Conditions Studied

Advanced Solid Tumor

Interventions

  • BIOLOGICAL Nivolumab
  • BIOLOGICAL RP3

Study Locations (13)

Other

  • Laboratoire de Recherche Translationnelle en Immunotherapie (LRTI), Gustave Roussy - Villejuif
  • University of Athens - Athens
  • University General Hospital Attikon - Athens
  • Vall d'Hebron Hospital Hospital Universitario Vall d´Hebron (Vall d'Hebron University Hospital) - Barcelona
  • Hospital Clinic Barcelona - Barcelona
  • START Madrid CIO Clara Campal, Hospital Universitario HM Sanchinarro Unidad de Ensayos Fase I Panta 3 - Madrid
  • Hospital Clinico Universitario de Valencia - Valencia
  • The Royal Marsden NHS Foundation Trust - London
  • Churchill Hospital - Oxford

Iowa

  • University of Iowa - Iowa City

Pennsylvania

  • UPMC Hillman Cancer Center - Pittsburgh

Texas

  • MD Anderson Cancer Center - Houston

Merseyside

  • The Clatterbridge Cancer Centre NHS Foundation Trust - Bebington

Trial Details

FieldValue
Enrollment Target 123 participants
Start Date 2020-12-29
Est. Completion 2026-11-30
Phase Phase 1

Sponsor

Replimune

9 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04735978

The ClinicalTrials.gov registry entry for NCT04735978 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 123 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (36% lower). The listed sponsor is Replimune, which has 9 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Nivolumab is the first listed.

NCT04735978 reports 13 study locations spanning 5 distinct geographic areas - top geographies include Other, Iowa, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04735978 about?

NCT04735978 is a clinical study titled "Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours". This is a Phase 1, multicenter, open label, single agent dose escalation and combination treatment study of RP3 in adult participants with advanced solid tumors, to evaluate the safety and tolerability of RP3 both as a single agent and in combination with anti-PD1 therapy and to determine the recomm...

What is the current status of trial NCT04735978?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 123 participants. The study started on 2020-12-29. Estimated completion is 2026-11-30.

What conditions does trial NCT04735978 study?

This clinical trial studies the following conditions: Advanced Solid Tumor.

What interventions are being tested in trial NCT04735978?

The interventions under investigation include: Nivolumab (BIOLOGICAL), RP3 (BIOLOGICAL).

Who is sponsoring clinical trial NCT04735978?

This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04735978 being conducted?

This trial has 13 study locations across Iowa, Pennsylvania, Texas, Merseyside. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Advanced Solid Tumor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Advanced Solid Tumor

All registered trials for this condition

Iowa

All trials with a study site in Iowa

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.